{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT03391466_ZUMA7\\NCT03391466_ZUMA7_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Full Analysis Set",
        "text": "The Full Analysis Set (FAS) includes all subjects randomized to the study. Subjects will be analyzed according to the treatment group to which they were randomized.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "populationDescription": "The Full Analysis Set (FAS) includes all subjects randomized to the study. Subjects will be analyzed according to the treatment group to which they were randomized.",
        "criteria": "All randomized subjects"
      },
      {
        "id": "pop_2",
        "name": "Safety Analysis Set",
        "text": "The Safety Analysis Set includes all subjects who received any dose of axicabtagene ciloleucel (test arm) or any dose of protocol-defined salvage chemotherapy (control arm). Subjects will be analyzed according to the treatment they actually received.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "populationDescription": "The Safety Analysis Set includes all subjects who received any dose of axicabtagene ciloleucel (test arm) or any dose of protocol-defined salvage chemotherapy (control arm). Subjects will be analyzed according to the treatment they actually received.",
        "criteria": "Received at least one dose of study treatment (axicabtagene ciloleucel or salvage chemotherapy)"
      },
      {
        "id": "pop_3",
        "name": "Safety Analysis Set - ASCT",
        "text": "The Safety Analysis Set - ASCT includes all subjects in the control arm who received high-dose therapy (HDT) and autologous stem cell transplant (ASCT).",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF-ASCT",
        "populationDescription": "The Safety Analysis Set - ASCT includes all subjects in the control arm who received high-dose therapy (HDT) and autologous stem cell transplant (ASCT).",
        "criteria": "Control arm subjects who received HDT and ASCT"
      },
      {
        "id": "pop_4",
        "name": "QoL Analysis Set",
        "text": "The QoL Analysis Set includes all subjects in the FAS who have a baseline and at least one post-baseline QoL assessment.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "QoL Set",
        "populationDescription": "The QoL Analysis Set includes all subjects in the FAS who have a baseline and at least one post-baseline QoL assessment.",
        "criteria": "Randomized AND baseline QoL assessment AND >=1 post-baseline QoL assessment"
      },
      {
        "id": "pop_5",
        "name": "Retreatment Analysis Sets",
        "text": "The Retreatment Analysis Sets include subjects who meet protocol-defined criteria for retreatment and receive a second course of study treatment.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "Retreatment Set",
        "populationDescription": "The Retreatment Analysis Sets include subjects who meet protocol-defined criteria for retreatment and receive a second course of study treatment.",
        "criteria": "Met retreatment criteria AND received second course of treatment"
      },
      {
        "id": "pop_6",
        "name": "Subgroup Analysis Sets",
        "text": "Subgroup analysis sets are defined based on baseline characteristics and stratification factors, including response to first-line therapy and second-line age-adjusted International Prognostic Index (IPI).",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "Subgroups",
        "populationDescription": "Subgroup analysis sets are defined based on baseline characteristics and stratification factors, including response to first-line therapy and second-line age-adjusted International Prognostic Index (IPI).",
        "criteria": "Defined by baseline covariates or stratification factors"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age at randomization",
        "code": "AGE_AT_RANDOMIZATION",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age at randomization",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Age categorized as >= 65 or < 65 years"
      },
      {
        "id": "char_2",
        "name": "Response to first-line therapy",
        "code": "RESPONSE_TO_FIRST-LI",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Response to first-line therapy",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Primary refractory vs relapse <= 6 months vs relapse > 6 and <= 12 months"
      },
      {
        "id": "char_3",
        "name": "Second-line age-adjusted IPI",
        "code": "SECOND-LINE_AGE-ADJU",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Second-line age-adjusted IPI",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "International Prognostic Index score (0 to 1 versus 2 to 3)"
      },
      {
        "id": "char_4",
        "name": "ECOG performance status",
        "code": "ECOG_PERFORMANCE_STA",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "ECOG performance status",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Performance status at screening (0, 1)"
      }
    ],
    "summary": {
      "populationCount": 6,
      "characteristicCount": 4
    }
  }
}